Industry News
Biotechnology Industry News
Unwelcome surprise for Vertex as FDA slaps hold on phase 1/2 diabetes cell therapy study
Unwelcome surprise for Vertex as FDA slaps hold on phase 1/2 diabetes cell therapy study aarmstrong Mon, 05/02/2022 - 10:23
Eyelid mites no match for Tarsus eye drop, as phase 3 data spurs drive to FDA
Eyelid mites no match for Tarsus eye drop, as phase 3 data spurs drive to FDA mbayer Mon, 05/02/2022 - 10:16
Eyelid mites no match for Tarsus eye drop, as phase 3 data spur drive to FDA
Eyelid mites no match for Tarsus eye drop, as phase 3 data spur drive to FDA mbayer Mon, 05/02/2022 - 10:16
Sage, Biogen get rolling on FDA submission for depression med
Sage, Biogen get rolling on FDA submission for depression med aarmstrong Mon, 05/02/2022 - 09:46
Gilead follows Big Pharma peers to Dragonfly’s pond in $300M deal for natural killer cell engagers
Gilead follows Big Pharma peers to Dragonfly's pond in $300M deal for natural killer cell engagers aarmstrong Mon, 05/02/2022 - 09:10
Stealth stumbles again as age-related macular degeneration joins list of clinical trial flops
Stealth stumbles again as age-related macular degeneration joins list of clinical trial flops ntaylor Mon, 05/02/2022 - 08:53
After posting midphase data, Rezolute banks $130M to take treatment for rare disease into pivotal trial
After posting midphase data, Rezolute banks $130M to take treatment for rare disease into pivotal trial ntaylor Mon, 05/02/2022 - 07:40
Seeing green: Breakthrough Properties raises $3B to build in biotech
Seeing green: Breakthrough Properties raises $3B to build in biotech gmasson Fri, 04/29/2022 - 16:19
Human testing for Praxis’ lead epilepsy drug held up after FDA clinical hold
Human testing for Praxis' lead epilepsy drug held up after FDA clinical hold gmasson Fri, 04/29/2022 - 12:11
AstraZeneca will have to wait a little longer for fruit from $3.5B Ionis ATTR partnership
AstraZeneca will have to wait a little longer for fruit from $3.5B Ionis ATTR partnership aarmstrong Fri, 04/29/2022 - 12:04
AbbVie’s cystic fibrosis long-game doesn’t pay off, as Galapagos med fails in triple combo
AbbVie's cystic fibrosis long-game doesn't pay off, as Galapagos med fails in triple combo aarmstrong Fri, 04/29/2022 - 11:02
While BMS waits for TYK2 inhibitor’s psoriasis nod, a new path potentially clears in lupus
While BMS waits for TYK2 inhibitor’s psoriasis nod, a new path potentially clears in lupus mbayer Fri, 04/29/2022 - 10:29
Genocea’s Atlas no longer holding up sky, as biotech moves for sell off
Genocea's Atlas no longer holding up sky, as biotech moves for sell off aarmstrong Fri, 04/29/2022 - 10:00
Finch’s C. diff drug cleared of FDA hold, but loose ends leave timing for phase 3 restart unclear
Finch's C. diff drug cleared of FDA hold, but loose ends leave timing for phase 3 restart unclear aarmstrong Fri, 04/29/2022 - 08:46
AstraZeneca kicks off work on 1,500-person R&D center in Kendall Square
AstraZeneca kicks off work on 1,500-person R&D center in Kendall Square ntaylor Fri, 04/29/2022 - 04:54
‘Serious missteps’: All Blue makes case for $773M Zymeworks buyout in wake of flagging stock
‘Serious missteps’: All Blue makes case for $773M Zymeworks buyout in wake of flagging stock ntaylor Fri, 04/29/2022 - 03:54
Chutes & Ladders—Merck loses another top exec, this time to Moderna
Chutes & Ladders—Merck loses another top exec, this time to Moderna mbayer Thu, 04/28/2022 - 17:33
Researchers take heart from mRNA’s potential to boost recovery from cardiac attack
Researchers take heart from mRNA's potential to boost recovery from cardiac attack gmasson Thu, 04/28/2022 - 15:29
With the makings of a hub, NYC primed to be life sciences leader
With the makings of a hub, NYC primed to be life sciences leader mwen Thu, 04/28/2022 - 12:48
Sanofi moves patients out of Ukraine warzone in ‘Herculean effort’ to preserve MS trials
Sanofi moves patients out of Ukraine warzone in 'Herculean effort' to preserve MS trials jwaldron Thu, 04/28/2022 - 12:46